AlphanoxLtd Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for AlphanoxLtd.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Medical Equipment earnings growth35.5%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Investors Don't See Light At End Of Alphanox Co.,Ltd.'s (KOSDAQ:043100) Tunnel And Push Stock Down 27%

Sep 30
Investors Don't See Light At End Of Alphanox Co.,Ltd.'s (KOSDAQ:043100) Tunnel And Push Stock Down 27%

Is Solco Biomedical (KOSDAQ:043100) Using Debt In A Risky Way?

Jun 27
Is Solco Biomedical (KOSDAQ:043100) Using Debt In A Risky Way?

Solco Biomedical Co., Ltd.'s (KOSDAQ:043100) 27% Dip In Price Shows Sentiment Is Matching Revenues

Jun 27
Solco Biomedical Co., Ltd.'s (KOSDAQ:043100) 27% Dip In Price Shows Sentiment Is Matching Revenues

Solco Biomedical Co., Ltd.'s (KOSDAQ:043100) Share Price Boosted 40% But Its Business Prospects Need A Lift Too

Feb 27
Solco Biomedical Co., Ltd.'s (KOSDAQ:043100) Share Price Boosted 40% But Its Business Prospects Need A Lift Too

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as AlphanoxLtd has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

KOSDAQ:A043100 - Analysts future estimates and past financials data (KRW Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/202427,314-18,896-10,001-8,522N/A
3/31/202427,721-18,326-9,009-7,450N/A
12/31/202326,878-19,966-10,640-9,044N/A
9/30/202325,504-11,733-9,384-8,278N/A
6/30/202324,869-11,049-8,821-8,088N/A
3/31/202323,869-10,519-8,361-7,669N/A
12/31/202223,396-9,528-6,382-5,463N/A
9/30/202223,974-6,299-8,067-6,745N/A
6/30/202223,501-5,836-8,415-7,242N/A
3/31/202223,769-4,983-6,911-6,011N/A
12/31/202123,951-4,075-6,286-5,411N/A
9/30/202123,798-175-3,528-3,184N/A
6/30/202124,316-530-1,796-1,474N/A
3/31/202123,2091,188-3,838-2,243N/A
12/31/202022,8541,647-5,530-4,080N/A
9/30/202021,555-11,256-7,567-6,050N/A
6/30/202021,158-11,587-7,920-6,389N/A
3/31/202021,756-16,841-6,833-6,216N/A
12/31/201921,442-18,764-8,342-6,739N/A
9/30/201921,333-16,920-9,728-7,611N/A
6/30/201922,344-17,837-11,421-8,843N/A
3/31/201922,222-15,641-11,751-8,935N/A
12/31/201822,541-15,350-14,435-7,604N/A
9/30/201823,551-6,445-14,347-6,521N/A
6/30/201823,007-7,231-14,289-5,898N/A
3/31/201823,822-7,613N/A-6,898N/A
12/31/201723,211-8,528N/A-8,345N/A
9/30/201722,857-9,593N/A-9,243N/A
6/30/201722,554-9,058N/A-10,115N/A
3/31/201722,204-8,935N/A-7,780N/A
12/31/201623,722-7,983N/A-6,202N/A
9/30/201624,189-8,432N/A-4,762N/A
6/30/201624,174-8,403N/A-2,984N/A
3/31/201622,986-7,838N/A-4,339N/A
12/31/201522,432-7,006N/A-4,164N/A
9/30/201525,154-1,094N/A-1,809N/A
6/30/201525,063-2,227N/A-1,696N/A
3/31/201527,940-1,782N/A22N/A
12/31/201430,141-2,175N/A2,222N/A
9/30/201431,154-7,426N/A633N/A
6/30/201433,051-5,588N/A692N/A
3/31/201434,506-5,474N/A2,158N/A
12/31/201335,499-5,016N/A437N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if A043100's forecast earnings growth is above the savings rate (2.7%).

Earnings vs Market: Insufficient data to determine if A043100's earnings are forecast to grow faster than the KR market

High Growth Earnings: Insufficient data to determine if A043100's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if A043100's revenue is forecast to grow faster than the KR market.

High Growth Revenue: Insufficient data to determine if A043100's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if A043100's Return on Equity is forecast to be high in 3 years time


Discover growth companies